TG Therapeutics Inc [TGTX] stock is trading at $30.74, up 6.70%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TGTX shares have gain 26.19% over the last week, with a monthly amount glided 38.59%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on October 29, 2024, when TD Cowen initiated its Buy rating and assigned the stock a price target of $50. Previously, Goldman upgraded its rating to Neutral on August 02, 2023, and dropped its price target to $12. BofA Securities started tracking the stock assigning a Underperform rating and suggested a price target of $5 on May 20, 2022. B. Riley Securities reiterated its recommendation of a Buy and reduced its price target to $35 on February 23, 2022. Goldman downgraded its rating to Sell for this stock on November 15, 2021, and downed its price target to $26. In a note dated April 20, 2021, Goldman initiated an Neutral rating and provided a target price of $50 on this stock.
TG Therapeutics Inc [TGTX] stock has fluctuated between $9.81 and $28.92 over the past year. Currently, Wall Street analysts expect the stock to reach $27.6 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $30.74 at the most recent close of the market. An investor can expect a potential drop of -10.21% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
TG Therapeutics Inc [NASDAQ:TGTX] reported sales of 264.79M for the trailing twelve months, which represents a drop of -49.41%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.0%, Pretax Profit Margin comes in at -0.05%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.08 and Total Capital is -0.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.65 points at the first support level, and at 28.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.38, and for the 2nd resistance point, it is at 32.02.
Ratios To Look Out For
For context, TG Therapeutics Inc’s Current Ratio is 4.59. In addition, the Quick Ratio stands at 3.91 and the Cash Ratio stands at 1.57. Considering the valuation of this stock, the price to sales ratio is 18.66, the price to book ratio is 24.92.
Transactions by insiders
Recent insider trading involved Echelard Yann, Director, that happened on Nov 05 ’24 when 20000.0 shares were sold. Director, Echelard Yann completed a deal on Nov 05 ’24 to buy 20000.0 shares. Meanwhile, Director Lonial Sagar sold 16348.0 shares on Jun 20 ’24.
